Press Release FeedGet the RSS feed
Menu

Business Wire

Abridge Makes Context-Aware Clinical Intelligence Available to Every Clinician at Partner Health Systems

Business Wire

More than 300 enterprise health systems that represent over 250 million patients have adopted Abridge's context-aware clinical decision support since launch in April.

SAN FRANCISCO, August 17, 2026--Today, Abridge announced that partner health systems can extend its clinical intelligence agent to every clinician across their organizations, regardless of how that clinician documents visits today. Health systems can make the agent available through the EHR workflow clinicians already use, or on a new mobile and web experience, each connected to the patient's chart as part of a single organizational decision rather than a clinician-by-clinician rollout.

"Adoption of decision support has outpaced anything we've shipped before because it feels like a natural extension of Abridge. It understands the context of the patient in front of the clinician, it's grounded in the evidence they already trust, and it connects to what they want to do next," said Dr. Shiv Rao, CEO and Co-Founder of Abridge, and a practicing cardiologist. "Our partners asked us to put that experience in the hands of their entire care team: clinical intelligence that is loved by users, embraced by leaders, and ready for every clinician at an Abridge health system."

Clinicians across more than 300 enterprise health systems have adopted Abridge's decision support capabilities since launch in April. Monthly active users have grown to more than half of eligible Abridge clinicians, and queries per clinician have tripled in the last two months.

"Our Abridge deployment is enterprise-wide, so every clinician at UPMC has access to the clinical intelligence agent," said Dr. Rob Bart, CMIO, UPMC Health Services Division. "More than 60% of our Abridge users have adopted it largely through self-discovery, with no additional training or campaign behind it. This only happens when the tool is embedded in the workflow, not adjacent, requiring extra steps to invoke or use. The more clinicians use it, the more it reinforces itself."

"The value of Abridge's clinical decision support is that it shows up at the exact moment a clinician needs it, with context that is specific to the patient in front of them," said Dr. Eric Poon, Chief Health Information Officer at Duke Health. "We've seen it help clinicians manage cases as different as a rare neurologic presentation and an unusual facial rash by recognizing the clinical context, surfacing relevant guidance in real time, and supporting the next best action. The clinician never has to step away from the patient to go find it."

  1. Biotech & pharmaGenmab A/SGenmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal CancerPetosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients COPENHAGEN, Denmark, October
  2. Agenus Inc.Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population Side effects were mostly mild and manageable, and all 18 patients proceeded to surgery Netherlands Cancer Institute investigators are now enroll
  3. HealthcareXencor, Inc.Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors-- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 -- -- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozan
  4. SaaSFrontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026FMC-376 is an equipotent ON+OFF KRAS G12C inhibitor designed with the Frontier™ Platform to address limitations of current KRAS G12C inhibitors, including resistance and tolerability Treatment with FMC-376 in the Phase 1A portion of the trial led to confirmed overall objective response rate of 56% in NSCLC patients, inclu
  5. Biotech & pharmaPfizer Inc.Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Companies: PfizerInvestigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S. NEW YORK, October 24, 2026--Pfizer I
  6. Biotech & pharmaIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer WILMINGTON, Del., October 24, 2026--Landmark re